53.9 F
New York
Friday, September 30, 2022

Date:

Share:

Serpin Pharma Awarded Competitive NCI Grant for SP16

Related Articles

Planned Parenthood Hudson Peconic Launches New Prenatal Program

Elmsford, NY, September 29, 2022 --(PR.com)-- Planned Parenthood Hudson Peconic (PPHP) is proud to announce the launch of CenteringPregnancy, a unique and innovative style of...

Viki B. Zarkin Recognized as a Mentor of the Year for 2022 by P.O.W.E.R.(Professional Organization of Women of Excellence Recognized)

Harrisburg, PA, September 29, 2022 --(PR.com)-- Viki B. Zarkin of Harrisburg, Pennsylvania has been recognized as a Mentor of the Year for 2022 by P.O.W.E.R....
Manassas, VA, September 20, 2022 –(PR.com)– The National Cancer Institute awarded Serpin Pharma a $400,000 competitive R43 grant for the Pre-clinical validation of phase II peptide LRP-1 agonist to treat and prevent chemotherapy-induced peripheral neuropathy.

The Principal Investigators are Serpin Pharma’s CEO and Executive Chairperson, Dr. Cohava Gelber and collaborator, Dr. Wendy Campana, Professor of Anesthesiology and Program in Neuroscience at the University of California, San Diego.

Chemotherapy-induced peripheral neuropathy (CIPN) is one of the most frequently experienced adverse side effect of patients receiving cancer treatments. Peripheral Neuropathy is the result of damage to the peripheral nerves and is associated with tingling, numbness, weakness, and pain, typically occurring in the hands and feet. Because of the chronic pain and other symptoms associated with CIPN, effective doses of chemotherapeutic agents are…

Read more…

Popular Articles